甘氨双唑钠对食管癌同步放化疗增敏疗效与安全性的Meta分析

doi:10.3760/cma.j.issn.1673422X.2016.12.006

摘要/Abstract

摘要： 目的系统评价甘氨双唑钠（CMNa）对食管癌同步放化疗增敏作用的临床疗效和安全性。方法检索中国生物医学文献数据库、中国期刊全文数据库（CNKI）、万方医药期刊全文数据库、维普中文科技期刊数据库、PubMed、Cochrane Library、EMBase，收集同步放化疗联合CMNa与不联合CMNa治疗食管癌的临床随机对照试验（RCT）。根据纳入排除标准筛选文献，对符合条件的RCT由两位研究者独立进行资料提取和质量评价后，采用RevMan 5.3进行Meta分析。结果共有4篇RCT、262例患者纳入研究。Meta分析结果显示同步放化疗联合CMNa增敏组的完全缓解率（OR=2.09，95%CI为1.24~3.54，Z=2.76，P=0.006）和总有效率（OR=2.75，95%CI为1.39~5.44，Z=2.90，P=0.004）均优于非增敏组，差异有统计学意义；两组1年生存率差异无统计学意义（OR=1.85，95%CI为0.94~3.64，Z=1.77，P=0.08）；两组消化道不良反应（OR=0.92，95%CI为0.49~1.70，Z=0.28，P=0.78）、骨髓抑制（OR=0.69，95%CI为0.39~1.19，Z=1.33，P=0.18）、肝功能损伤（OR=0.93，95%CI为0.48~1.79，Z=0.23，P=0.82）、放射性食管炎（OR=1.07，95%CI为0.58~2.00，Z=0.22，P=0.82）、放射性肺炎（OR=0.76，95%CI为0.29~1.98，Z=0.56，P=0.57）、放射性皮肤损伤（OR=1.11，95%CI为 0.51~2.43，Z=0.26，P=0.80）的发生率差异均无统计学意义。结论同步放化疗联合CMNa增敏治疗食管癌近期疗效好，且不增加不良反应的发生。

关键词: 食管肿瘤, 辐射增敏药, Meta分析, 同步放化疗

Abstract: ObjectiveTo assess the efficacy and safety of chemoradiotherapy combined with sodium glycididazole (CMNa) for the patients with esophageal carcinoma by conducting a Metaanalysis. MethodsBy searching Chinese Biomedical Database, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, PubMed, Cochrane Library and EMBase, we collected randomized clinical controlled studies (RCTs) of chemoradiotherapy combined with CMNa and control group without CMNa in the treatment of esophageal carcinoma. According to the inclusion and exclusion criteria, data extraction and quality assessment were done by two researchers independently. Metaanalysis was performed by using Revman 5.3. ResultsA totle of 4 RCTs involving 262 patients were included. The Metaanalysis results showed that chemoradiotherapy combined with CMNa group had better complete remission rate (OR＝2.09, 95%CI: 1.243.54, Z=2.76, P=0.006) and overall response rate (OR=2.75, 95%CI: 1.395.44, Z=2.90, P=0.004) than the control group, with significant differences. The 1year survival rates of the two groups were similar, with no significant difference (OR＝1.85, 95%CI: 0.943.64, Z=1.77, P=0.08). There were no significant differences in the incidence rates of adverse reactions such as gastrointestinal adverse reaction (OR=0.92, 95%CI: 0.491.70, Z=0.28, P=0.78), bone marrow suppression (OR=0.69, 95%CI: 0.391.19, Z=1.33, P=0.18), liver damage (OR=0.93, 95%CI: 0.481.79, Z=0.23, P=0.82), radioactive esophagitis (OR=1.07, 95%CI: 0.582.00, Z=0.22, P=0.82 ), radioactive pneumonia (OR=0.76, 95%CI: 0.291.98, Z=0.56, P=0.57) and radioactive skin lesion (OR=1.11, 95%CI: 0.512.43, Z=0.26, P=0.80). ConclusionIn the treatment of esophageal carcinoma, chemoradiotherapy combined with CMNa has a good shortterm effect, and does not increase the occurrence of adverse reactions.

Key words: Esophageal neoplasms, Radiationsensitizing agents, Metaanalysis, Chemoradiotherapy

李辉, 刘婧, 吴栋文, 廖梦婷, 吴文悦, 杨梦玲, 叶琳, 施舒鹏, 申良方. 甘氨双唑钠对食管癌同步放化疗增敏疗效与安全性的Meta分析[J]. 国际肿瘤学杂志, 2016, 43(12): 904-910.

LI Hui, LIU Jing, WU Dong-Wen, LIAO Meng-Ting, WU Wen-Yue, YANG Meng-Ling, YE Lin, SHI Shu-Peng, SHEN Liang-Fang. Efficacy and safety of sodium glycididazole for esophageal carcinoma chemoradiotherapy: a Metaanalysis[J]. Journal of International Oncology, 2016, 43(12): 904-910.

参考文献

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87108. DOI: 10.3322/caac.21262. ［2］ Tang WR, Fang JY, Wu KS, et al. Epidemiological characteristics and prediction of esophageal cancer mortality in China from 1991 to 2012［J］. Asian Pac J Cancer Prev, 2014, 15(16): 69296934. ［3］ Kato H, Nakajima M. Treatments for esophageal cancer: a review［J］. Gen Thorac Cardiovasc Surg, 2013, 61(6): 330335. DOI: 10.1007/s1174801302460. ［4］ Ajani JA, Barthel JS, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers［J］. J Natl Compr Canc Netw, 2011, 9(8): 830887. ［5］ Almhanna K, Shridhar R, Meredith KL. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?［J］. Cancer Control, 2013, 20(2): 8996. ［6］ Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated metaanalysis［J］. Lancet Oncol, 2011, 12(7): 681692. DOI: 10.1016/S14702045(11)701425. ［7］ Zeng YC, Wu R, Xu ZG, et al. Safety and radiationenhancing effect of sodium glycididazole in locoregionally advanced laryngeal cancers previously treated with platinumcontaining chemotherapy regimens: a preliminary report［J］. Cancer Radiother, 2010, 14(1): 5964. DOI: 10.1016/j.canrad.2009.06.022. ［8］鹿红, 赵迪, 于大海, 等. 甘氨双唑钠联合同期放化疗治疗局部中晚期食管癌的临床观察［J］. 临床肿瘤学杂志, 2014, 19(10): 921924. ［9］张红生. 甘氨双唑钠联合同步放化疗治疗局部中晚期食管癌临床分析［J］. 现代肿瘤医学, 2012, 20(1): 9193. DOI: 10.3969/j.issn.16724992.2012.01.30. ［10］赵兴, 周毛, 王立平, 等. 甘氨双唑钠增敏食管癌后程加速超分割放疗协同化疗的临床研究［J］. 实用肿瘤杂志, 2012, 27(4): 358361. DOI: 10.13267/j.cnki.syzlzz.2012.04.019. ［11］梁军, 韩春, 王凤英, 等. 注射用甘氨双唑钠在胸段食管鳞癌同步化放疗中增敏作用的多中心、随机双盲的Ⅱ期临床研究［J］. 癌症进展, 2011, 9(6): 699706. DOI: 10.3969/j.issn.16721535.2011.06.021. ［12］ Eisenhauer EA, Therasse P, Bogaerts J, et al, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)［J］. Eur J Cancer, 2009, 45(2): 228247. DOI: 10.1016/j.ejca.2008.10.026. ［13］ Hiratsuka S. Vasculogenensis, angiogenesis and special features of tumor blood vessels［J］. Front Biosci (Landmark Ed), 2011, 16: 14131427. ［14］ Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis［J］. Cell, 1996, 86(3): 353364. ［15］ Yeh JJ, Kim WY. Targeting tumor hypoxia with hypoxiaactivated prodrugs［J］. J Clin Oncol, 2015, 33(13): 15051508. DOI: 10.1200/JCO.2014.60.0759. ［16］ Xing L, Wu P, Sun X, et al. Improve the effect of radiation therapy for recurrent esophageal squamous cell carcinoma with sodium glycididazole［J］. Inter J Radia Oncol Biol Phys, 2014, 90(1): S802S803. DOI: http://dx.doi.org/10.1016/j.ijrobp.2014.05.2316. ［17］ Zeng YC, Wu R, Xing R, et al. Radiationenhancing effect of sodium glycididazole in patients suffering from nonsmall cell lung cancer with multiple brain metastases: a randomized, placebocontrolled study［J］. Cancer Radiother, 2016, 20(3): 187192. DOI: 10.1016/j.canrad.2016.02.008. ［18］ Liu MZ, He LR, Lu TX, et al. Effect of hypoxic radiosensitizer sodium glycididazole on longterm result of radiotherapy for nasopharyngeal carcinoma［J］. Zhonghua Zhong Liu Za Zhi, 2006, 28(12): 932937. ［19］ Zeng YC, Xing R, Zeng J, et al. Sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway［J］. Tumour Biol, 2015, 37(5): 58695878. DOI: 10.1007/s1327701542781. ［20］蒋俊, 权循凤, 张丽, 等. 放疗联合甘氨双唑钠增敏治疗食管鳞癌的Meta分析［J］. 中华临床医师杂志: 电子版, 2013, 7(13): 59935997. DOI: 10.3877/cma.j.issn.16740785.2013.13.122. ［21］罗和生, 蒙建超, 童强. 甘氨双唑钠对食管癌放射治疗增敏作用的Meta分析［J］. 临床消化病杂志, 2012, 24(4): 223227. DOI: 10.3870/lcxh.j.issn.1005541X.2012.04.10.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[3]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[4]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[5]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[6]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[7]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[8]	巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.
[9]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟. 基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[10]	戴李宸, 胡莉钧, 于静萍. 尼妥珠单抗治疗食管鳞状细胞癌的应用进展[J]. 国际肿瘤学杂志, 2022, 49(8): 484-489.
[11]	夏玲玲, 陈永顺, 李彬, 宁婷婷, 张蔡羽天. pN₊食管鳞状细胞癌患者R0切除术后放化疗与化疗的安全性及有效性比较[J]. 国际肿瘤学杂志, 2022, 49(6): 334-339.
[12]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 肌肉减少症对老年食管癌患者根治性放疗临床疗效及预后的影响[J]. 国际肿瘤学杂志, 2022, 49(4): 199-205.
[13]	周剑烽, 王铁君. 食管癌的靶向治疗及免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(4): 237-242.
[14]	刘佳, 葛小林, 狄晓珂, 史玉静, 曾玉婷. 喜炎平注射液预防放射性食管炎的疗效分析[J]. 国际肿瘤学杂志, 2022, 49(3): 146-150.
[15]	张俊鹏, 于燕燕, 李宝生. lncRNA、circRNA调控食管鳞状细胞癌放化疗敏感性的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 185-189.